IMAG

HF

Workshop

WHEN SHOULD WE TAKE ADVANTAGE OF PERCUTANEOUS THERAPIES FOR VALVULAR HEART DISEASE IN OUR PATIENTS? FOCUS ON THE MITRAL AND TRICUSPID VALVES

Co-Chair(s)

• Nicolo P.

  Nicolo Piazza, MD

  Dr
• Gillian N.

  Gillian Nesbitt, MD FRCPC FACC FASE

  Director of Echocardiography Sinai Health System
  University of Toronto

Presenter(s)

• Wendy T.

  Wendy Tsang, MD

  Cardiologist
  University of Toronto
• Karima A.

  Karima Addetia, MD

  Assistant Professor
• Geraldine O.

  Geraldine Ong, MD

  Cardiologist, Assistant Professor of Medicine
  St. Michael's Hospital, University of Toronto

Planning Committee Member(s)

• Kalie K.

  Kalie Kebed, MD

  Cardiology Fellow

Percutaneous therapies for both native and prosthetic valve dysfunction are gaining credibility in the literature and companies are racing against each other to produce the next state-of-the-art prosthetic valve. While much of this work occurs in highly specialized academic centers the patients who need these therapies come from all over the country. The purpose of this workshop is to share the some of the patient-selection expertise that has been garnered over the recent past by experts in the field with cardiologists who deal with patients like these in their daily practice. The goal being to better equip the community to work-up these patients and to spark discussion on how we should be selecting patients for these therapies in the future. It is the aim of this workshop to also impart knowledge tips on how to image these patients and what to look for before sending them for one of these therapies.

Co-chairs: Niccolo Piazza, Gillian Nesbitt

(15 + 5 min questions)
MItraClip: Who should/should not be considered? - Wendy Tsang

(15 + 5 min questions)
The dysfunctional prosthetic valve: The Percutaneous Option - Karima Addetia

(15 + 5 min questions)
Percutaneous Tricuspid Procedures: Where do they fit in? – Geraldine Ong

Target Audience(s):

Clinical cardiologists
Echocardiologists
Trainee (clinical)

Learning Objectives

At the conclusion of this session, participants will be able to:

• select patients for mitraclip therapy;
• select patients for percutaneous intervention on a prosthetic valve and predict whether an intervention will be successful; and
• summarize the experience so far with percutaneous tricuspid therapies and identify the patients who may benefit.